Abstract
Drug resistance hinders effectiveness of human ovarian cancer (OC) therapies, such as cisplatin or paclitaxel therapy. Although dacomitinib, a novel a......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
